Screener
Amylyx Pharmaceuticals, Inc. AMLX Total Cost of Revenue
Discontinued — last reported Q4 '25
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The source filing: Amylyx Pharmaceuticals, Inc.’s 10-K, filed March 3, 2026.
- Filed
- Mar 3, 2026, 7:10 AM EST
- Fiscal year
- FY2025
- Accession
- 0001193125-26-086645
| Line item | Year Ended December 31, 2025 | Year Ended December 31, 2024 |
|---|---|---|
| Product revenue, net | — | $87,371 |
| Operating expenses: | ||
| Cost of sales | — | 5,953 |
| Cost of sales - inventory impairment and loss on firm purchase commitments | — | 118,680 |
| Acquired in-process research and development | — | 36,203 |
| Research and development | 90,404 | 104,084 |
| Selling, general and administrative | 62,887 | 114,331 |
| Restructuring expenses | — | 22,851 |
Item 16. Form 10-K Summary
FAQ
- What is Amylyx Pharmaceuticals, Inc.'s total cost of revenue?
- Amylyx Pharmaceuticals, Inc. (AMLX) reported total cost of revenue of $0 in Q4 2025.
- What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s total cost of revenue?
- Over 2 years (2023 to 2025), Amylyx Pharmaceuticals, Inc.'s total cost of revenue has grown at a -100.0% compound annual growth rate (CAGR), from $25.44M to $0.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.
Ask your AI about Amylyx Pharmaceuticals, Inc.'s total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude